| Document |
Document Title |
|
WO/2024/023198A1 |
The present invention relates to a method reducing necrotic enteritis effect in a bird comprising administering an oligosaccharide preparation, and to an oligosaccharide preparation for use in treatment, amelioration and/or prophylaxis o...
|
|
WO/2024/024149A1 |
The purpose of the present invention is to provide a fatty liver disease inhibitor that exhibits excellent fatty liver disease inhibitory action while being considered to be safe and less harmful. A fatty liver disease inhibitor accordin...
|
|
WO/2024/025393A1 |
The present invention relates to a novel salt of an imidazo[1,2-a]pyridine compound, a crystalline form thereof, and a preparation method, the novel salt being azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimid
azo[1,2-a]pyridi...
|
|
WO/2024/023362A1 |
The present invention relates to novel fluoride salts of different amino acids or fluoride salts of amino acid esters and their compositions. These fluoride compounds and their compositions can be used as ingredients in products for mout...
|
|
WO/2024/026200A1 |
The present inventive concept provides methods for treating or preventing ulcerative colitis, systemic lupus erythematosus (SLE), sepsis, or post-sepsis syndrome including administering a therapeutically effective amount of dihydro-lipoi...
|
|
WO/2024/026395A1 |
Methods are provided for the treatment of moderate to severe ulcerative colitis or moderate to severe Crohn's disease with an antibody or antigen-binding fragment thereof that specifically binds to TNF-like ligand 1A (TL1A). Pharmaceutic...
|
|
WO/2024/022940A1 |
The invention relates to a composition which comprises glycosaminoglycans, a polysaccharide and a monosaccharide derivative of glucose. The invention also relates to its use as a medicament and, particularly, to its use as a gastroprotec...
|
|
WO/2024/025808A1 |
Disclosed are improved methods of making liver organoids, and methods of making population organoid panels which can be used, for example, for genotype-pheontype analysis or screening of test compounds. Also disclosed are methods of asse...
|
|
WO/2024/025961A1 |
The use of cannabis and/or its parts (e.g., cannabinoids, CBD, THC, cannabidiol, hemp) to treat or reduce the effects caused by exposure to glyphosate, glyphosate derivatives, glyphosate disorders, and/or glyphosate toxicity in the human...
|
|
WO/2024/019103A1 |
Provided is a compound that is effective as an active ingredient in a therapeutic pharmaceutical composition for pancreatic cancer. Having studied compounds that are effective as active ingredients in a therapeutic pharmaceutical compo...
|
|
WO/2024/017331A1 |
The present invention belongs to the fields of bioengineering and biological treatment. Disclosed are an anti-ADM monoclonal antibody or a fragment thereof and a pharmaceutical composition, a detection reagent, or a kit comprising the mo...
|
|
WO/2024/020170A1 |
Provided herein are compounds which can act agonists of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating inflammatory and autoimmune diseases and disorders, such as diseases or disorders of the gastr...
|
|
WO/2024/020388A1 |
Disclosed herein are formulations of small molecule GIP/GLP-1 dual receptor agonists and uses thereof.
|
|
WO/2024/018083A1 |
A vaccine comprising one or more VTEC immunogens. The vaccine is for use in vaccine therapy to treat or prevent VTEC infection in a mammal and for use in vaccine therapy to treat or prevent HUS in a mammal. A method of diagnosing VTEC in...
|
|
WO/2024/020372A1 |
Disclosed herein are small molecule GLP-1 receptor agonist compounds, pharmaceutical compositions, and the use and preparation thereof.
|
|
WO/2024/020284A1 |
A method of treating a microbial infection in a subject comprises administering to a subject in need thereof an effective amount of a composition comprising mycolactone (MLN). A method of preventing a microbial infection in a subject com...
|
|
WO/2024/019509A1 |
The present invention provides a pharmaceutical composition for preventing or treating metabolic diseases comprising a novel pan-PPAR agonist compound or a salt thereof as an active ingredient. As a pan-PPAR agonist, the compound or the ...
|
|
WO/2024/020466A1 |
The disclosure relates to methods and compositions that provide for bacterial populations with increased potential for engraftment into the gut of mammalian systems. Accordingly, aspects of the disclosure relate to a bacterial cell or po...
|
|
WO/2024/017227A1 |
Provided is a cannabinoid receptor compound as represented by formula I. The compound has a good ability to bind to the human CB2 receptor, and exhibits good agonistic activity and high selectivity on the CB2 receptor. Consequently, said...
|
|
WO/2024/018036A1 |
The present invention relates to a platform based on unicellular algae, grown in a controlled environment, which serve as a biofactory for the production of biologically active metabolites.
|
|
WO/2024/020197A1 |
The present disclosure provides pharmaceutical compositions comprising a microorganism capable of expressing one or more enzymes that convert salicin to saligenin, and salicin, or a pharmaceutically acceptable salt thereof. The present d...
|
|
WO/2024/020458A1 |
The present invention relates to the use of Apoptosis Signal-Regulating Kinase- 1 (ASK-1) inhibitor compounds for the treatment of organ diseases and disorders, wherein the organ disease or disorder is selected from a liver, heart diseas...
|
|
WO/2024/020243A1 |
Provided are methods and compositions for treating intestinal failure-associated liver disease in a subject, which may be by selective activation of the Liver X receptor (LXR) in the gut. Also provided are methods of selectively activati...
|
|
WO/2024/016113A1 |
It relates to sublingual mucus adhesion drug delivery technology. The technology involves the preparation of materials consisting of mucus adhesive excipient polymer chemically bonded with drug molecules and delivery of the materials to ...
|
|
WO/2024/018037A1 |
The present invention relates to a microalgae product capable of expressing glucagon-like peptide (GLP), preferably GLP-2, and its use in the pharmaceutical or nutraceutical field in the treatment and prevention of disorders affecting th...
|
|
WO/2024/019521A2 |
The present invention relates to a bowel cleansing composition and, specifically, to a bowel cleansing composition that reduces the dosage required on the day of examination where bowel cleansing is needed, thereby increasing safety.
|
|
WO/2024/019057A1 |
The purpose of the present invention is to provide an agent for improving intestinal flora, the agent being capable of improving intestinal flora by increasing the number of bacteria belonging to the genus Bifidobacterium and/or the genu...
|
|
WO/2024/017366A1 |
Provided are a compound of formula (I) having an effect of regulating and controlling the activity of 15-PGDH, a stereoisomer, a tautomer or a form of a mixture thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof...
|
|
WO/2024/013395A1 |
The application relates to pyrrolotriazine and imidazotriazine derivatives of the general formula (I) for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation...
|
|
WO/2024/015943A1 |
Disclosed are recombinant mutant isomaltase enzymes, and pharmaceutical compositions comprising an isomaltase enzyme, e.g., a recombinant mutant isomaltase enzyme, and an optional invertase enzyme. The enzymes and compositions can be use...
|
|
WO/2024/012423A1 |
Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and/or treating hepatiti...
|
|
WO/2024/015958A1 |
The present invention relates to novel cyclic peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimm...
|
|
WO/2024/011771A1 |
A composition for protecting gastrointestinal mucosa, resisting Helicobacter pylori and promoting gastrointestinal peristalsis, comprising the following components in parts by weight: 0.8-1 parts of Curcumae longae rhizoma extract, 1.6-2...
|
|
WO/2023/213284A9 |
Provided is an siRNA capable of inhibiting the expression of a 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) gene. The siRNA comprises a sense strand and an antisense strand. The sense strand and the antisense strand comprise a nu...
|
|
WO/2024/012425A1 |
The present invention relates to a compound, a pharmaceutical composition containing same, a preparation method therefor, and the use thereof as an RIPK1 inhibitor. The compound is a compound as represented by formula (I), or an optical ...
|
|
WO/2024/012589A1 |
The present disclosure relates to a polypeptide composition, a pharmaceutical, a pharmaceutical composition, and a use thereof. The polypeptide composition comprises a polypeptide, a protease inhibitor, vegetable oil and an absorption pr...
|
|
WO/2024/012421A1 |
Provided herein are pharmaceutical compositions comprising a quinolone compound for irritable bowel syndrome, especially provided is the use of the quinolone compound, in particular 1-cyclopropyl-6-fluoro-1, 4-dihydro-8-methyl-7- (2-amin...
|
|
WO/2024/013245A1 |
The present invention refers to polymeric reverse micelles for delivery of hydrophilic macromolecules. In particular, it relates to a polymeric reverse micelle for the delivery of an active pharmaceutical ingredient, wherein the interior...
|
|
WO/2024/015942A1 |
Disclosed are recombinant mutant invertase enzymes. Also disclosed are pharmaceutical compositions comprising an invertase enzyme, e.g., a recombinant mutant invertase enzyme, and an optional isomaltase enzyme. The enzymes and compositio...
|
|
WO/2024/012531A1 |
A use of a pyridone derivative. A use of a substance A in preparation of a drug, wherein the substance A is a compound as shown in formula I or a pharmaceutically acceptable salt thereof; and the drug is a drug for treating and/or preven...
|
|
WO/2024/013211A1 |
The present invention relates to Ligilactobacillus salivarius strains to provide relief from or prevent lactose induced abdominal discomfort; digest lactose or improve digestion of lactose; provide digestive comfort after digestion of la...
|
|
WO/2024/015416A1 |
The present disclosure relates to compounds that are derivatives of the compound, celastrol, of formula (I), wherein R is an amide group and pharmaceutical compositions that include these celastrol derivative compounds. The disclosure al...
|
|
WO/2024/013752A1 |
The present invention provides methods for treating a disease or condition in a subject in need thereof by partially inhibiting the silencing activity of at least two SIRT6-targeted miRNAs in said subject, thereby increasing SIRT6 protei...
|
|
WO/2024/009542A1 |
The present invention addresses the problem of providing a new injection liquid that is for dental local anesthesia and that is capable of reducing a patient's indefinite complaint that may be caused after a treatment, particularly an un...
|
|
WO/2024/010890A1 |
Described herein is method of treating, ameliorating and/or preventing a wound in a subject in need thereof. The method includes: collecting a first sample from the wound at a first timepoint and determining a first CCL1 (chemokine ligan...
|
|
WO/2024/011251A1 |
Methods for treating eosinophilic esophagitis in a pediatric subject are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R ...
|
|
WO/2024/008597A1 |
The present invention relates to a fermentation product obtained by a fermentation process of at least one bacterial strain in the presence of at least one vegetable extract. The fermentation product of a bacterial may comprise alimentar...
|
|
WO/2024/007629A1 |
The present invention relates to the field of plant trypsin inhibitors, and provides a polysaccharide trypsin inhibitor and a preparation method therefor. The polysaccharide trypsin inhibitor is obtained by separating and purifying massa...
|
|
WO/2024/010115A1 |
The present invention relates to a pharmaceutical composition containing a carbonated beverage for preventing or treating dysphagia, and reduces the activity start time of deglutition muscles, and increases action potential amplitude, an...
|
|
WO/2024/011136A1 |
Described herein are crystalline forms of 1-(5-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7
-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fl
uorocyclopropyl)urea adipate, and solvates thereof.
|
